Allergan sues Pfizer over opioid crisis lawsuits

pharmafile | August 3, 2018 | News story | Medical Communications Allergan, Litigation, Pfizer, lawsuits, opioid crisis, opioids 

Allergan are suing American pharma giant Pfizer over potential damages that they may be forced to pay relating to hundreds of lawsuits that have been filed against them over their alleged role in the opioid crisis.

Allergan, and others such as Purdue Pharma, could be forced make huge pay-outs to resolve lawsuits in which the opioid drug makers have been accused of misleading the public and creating a national health crisis. Allergan have been accused of improperly marketing the opioid painkiller Kadian in allegations dating back to the mid-1990s. Bloomberg Intelligence have estimated that settlements could total $50 billion, as the plaintiff’s lawyers have compared the situation to the one faced by tobacco companies during the latter half of the 20th century.

However, Allergan, who acquired the morphine based drug Kadian in 2008, have claimed that the alleged offences occurred before they acquired the opioid painkiller. As such the company are suing Pfizer, whose subsidiary King Pharmaceuticals have been blamed for improperly marketing the opioid drug.

Nevertheless Pfizer have announced that they reject any responsibility and that they will not compensate Allergan. The pharma giant announced in a statement: “Allergan’s claims relate to a product that Pfizer never manufactured, marketed or sold. Instead, they arise from a historical 2008 contract belonging to King Pharmaceuticals, a company we acquired in 2010.”

Louis Goss

Related Content

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

FDA approves prescription nasal spray for opioid overdose treatment

The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …

Latest content